Horse /

Breed profile · FDA CVM July 2026 extract

Paso Fino adverse-event record

Adverse-event filings for Paso Fino (Horse) in the FDA Center for Veterinary Medicine openFDA extract. Browse horse breeds, reactions, and outcomes below.

#284 of 510
by report volume (all breeds)
43
FDA CVM reports on file
2.3%
death-coded share of reports
7
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction

How the 43 reports break down

By recorded gender -- every report on file for Paso Fino, no filtering.

Annual report volume

Annual adverse-event report trend Yearly FDA CVM adverse-event report counts for this breed. 3 2.25 1.5 0.75 0 2017 2018 2019 2020 2021 2022 2023 2025 Reports filed Death-coded reports
Annual report volume for Paso Fino drawn from FDA CVM filings.

Data updated September 2026

The verdict

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Paso Fino ranks #283 of 510 by total reports (43). Death-coded-share rank requires at least 50 reports. National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).

93,675
Retriever - Labrador reports (#1)
99.0%
Atlantic Salmon (Salmo salar) death share (#1)
#283
This breed, reports of 510

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Paso Fino has 43 reports now versus 43 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Paso Fino changes

Total Reports

43

Below-median volume

Deaths Reported

1

of 43 reports

Death-coded share of reports

2.3%

2.3% death-coded

Avg Age at Report

16.6 yr

403.6 kg avg weight

Death-Coded Outcome Share

Paso Fino death-coded reports 2.3%
Cross-breed median

2.3% of 43 paso fino reports involved a death outcome.

How to read this number

Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.

Average weight at time of report: 403.6 kg (889.9 lbs)

Top Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 7
Injection site swelling 5
Overdose 5
Anorexia 4
Other abnormal test result NOS 4

Most Referenced Drugs

Pergolide Mesylate 10
Ivermectin(1.55%)/Praziquantel(7.75%) Paste 9
Ceftiofur Crystalline Free Acid 3
Omeprazole 3
Ceftiofur 2

Outcome Breakdown

Outcome Unknown
15 (44.1%)
Recovered/Normal
12 (35.3%)
Ongoing
6 (17.6%)
Died
1 (2.9%)

Gender Distribution

Male 29 (67.4%)
Female 14 (32.6%)

Reports by Year

Year Reports Trend
2010 4
2011 3
2012 5
2013 3
2014 2
2015 2
2016 8
2017 3
2018 3
2019 2
2020 1
2021 1
2022 2
2023 1
2025 3

Paso Fino: low death-coded share in the FDA CVM extract

Signature read: Paso Fino's 2.3% death-coded share is in the lower third of the ≥50-report cohort (median 4.8%). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Paso Fino sits at #284 of 510 by report volume among all breeds and #24 of 55 among horse breeds, with 43 reports and 1 (2.3%) death-coded. Mean age at report: 16.6 years, average weight 403.6 kg (889.9 lbs).

Top reported signs: Lethargy (see also Central nervous system depression in 'Neurological') (7), Injection site swelling (5), Overdose (5). Most-referenced drug: Pergolide Mesylate (10 reports), followed by Ivermectin(1.55%)/Praziquantel(7.75%) Paste (9) and Ceftiofur Crystalline Free Acid (3).

Outcome coding on 34 status-recorded reports is dominated by Outcome Unknown (44.1%). Annual submissions ranged 1-2,025 across 15 years on file.

Horse Breeds With a Similar Report Volume

Showing 6 of 54 horse breeds in our dataset, ranked by closest report volume.

Nationwide breeds with similar profiles

Two openFDA-derived peer sets for Paso Fino, both outside the Horse family so the neighborhoods are not species containment (the similar-volume list above stays within species).

Similar average weight

Nearest other-species breeds by reported average weight (403.6 kg here).

What to do with this horse

A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.

Frequently Asked Questions

How many FDA adverse event reports involve Paso Fino?
There are 43 adverse event reports involving Paso Fino in the FDA database, of which 1 were death-coded (2.3% of those reports). That is a share of REPORTED events, not a mortality rate for the breed: adverse events reach the FDA when something goes wrong, so the denominator is reports, never the population of animals. According to the same FDA CVM extract, Paso Fino ranks #284 of 510 by report volume among all breeds PlainBreed indexes (#24 of 55 among horse breeds).
Where does Paso Fino sit among other breeds in PlainBreed's corpus?
According to FDA CVM report volume, Paso Fino is #284 of 510 breeds indexed on PlainBreed (same ordering as the most-reported-breeds ranking). Inside Horse, it is #24 of 55. It has fewer than 50 reports, so it is outside the death-rate ranking cohort (≥50 reports). These are placement ranks in the reporting corpus, not clinical risk scores.
What are the most common adverse reactions reported for Paso Fino?
The most commonly reported adverse reactions for Paso Fino are Lethargy (see also Central nervous system depression in 'Neurological') (7 reports), Injection site swelling (5 reports), Overdose (5 reports), Anorexia (4 reports), Other abnormal test result NOS (4 reports).
What drugs are most frequently associated with Paso Fino adverse events?
The drugs most frequently referenced in Paso Fino adverse event reports are Pergolide Mesylate (10 reports), Ivermectin(1.55%)/Praziquantel(7.75%) Paste (9 reports), Ceftiofur Crystalline Free Acid (3 reports), Omeprazole (3 reports), Ceftiofur (2 reports).
What is the average age of Paso Fino in adverse event reports?
The average age of Paso Fino at the time of adverse event reports is 16.6 years, with an average weight of 403.6 kg (889.9 lbs).

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Paso Fino (Horse), extract as of July 2026 extract. 43 reports · 1 death-coded (2.3% of reports, not a mortality rate) · #284 of 510 by volume.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →